Milrinone has been proposed as an effective treatment for pulmonary hypertension (PH) and right ventricular (RV) dysfunction. We aimed to determine the effect of milrinone therapy on clinical and ...
A head-to-head comparison of inotropes in the setting of cardiogenic shock revealed no clear victor, with milrinone and dobutamine providing similar outcomes in the randomized DOREMI trial. A ...
Hyloris Pharmaceuticals SA, a specialty biopharma company, has acquired the global rights from the Baker Heart and Diabetes Institute (the Baker Institute), Melbourne, Australia, to CRD-102 (and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback